Latest Articles
FOCL: Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion - TradingView
FOCL: Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion TradingView
Published: June 4, 2026, 7:18 p.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - NT News
Women ‘blindsided’ as critical hormone therapy pulled from shelves NT News
Published: June 4, 2026, 4:21 a.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - The Cairns Post
Women ‘blindsided’ as critical hormone therapy pulled from shelves The Cairns Post
Published: June 4, 2026, 4:20 a.m.
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post
Published: June 3, 2026, 2:49 p.m.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily
Published: June 3, 2026, 3:15 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN
Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress
Published: June 1, 2026, 8 p.m.
FOCL: Robotic focal therapy platform drives rapid growth, clinical adoption, and expansion into new indications - TradingView
FOCL: Robotic focal therapy platform drives rapid growth, clinical adoption, and expansion into new indications TradingView
Published: June 1, 2026, 6:25 p.m.
FOCL: Robotic focal therapy drives rapid growth, expanding into new indications and global markets - TradingView
FOCL: Robotic focal therapy drives rapid growth, expanding into new indications and global markets TradingView
Published: June 1, 2026, 4:35 p.m.
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients - Cancer Therapy Advisor
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients Cancer Therapy Advisor
Published: May 30, 2026, 4 a.m.
Link copied to clipboard!